Top-News
Chemikalien Irland

Alkermes plc News

Aktie
WKN:  A1JKVH ISIN:  IE00B56GVS15 US-Symbol:  ALKS
22,30 €
+0,00 €
0,00%
20:34:20 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
167,08 Mio.
Marktkapitalisierung *
3,75 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 29.02.2024

Alkermes plc News

02.05.24 - PR Newswire
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk PR Newswire
02.05.24 - PR Newswire
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk PR Newswire
01.05.24 - PR Newswire
Alkermes plc Reports First Quarter 2024 Financial Results
Alkermes plc Reports First Quarter 2024 Financial Results PR Newswire
01.05.24 - PR Newswire
Alkermes plc Reports First Quarter 2024 Financial Results
Alkermes plc Reports First Quarter 2024 Financial Results PR Newswire
24.04.24 - PR Newswire
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 PR Newswire
24.04.24 - PR Newswire
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 PR Newswire
17.04.24 - PR Newswire
Alkermes to Report First Quarter Financial Results on May 1, 2024
Alkermes to Report First Quarter Financial Results on May 1, 2024 PR Newswire
17.04.24 - PR Newswire
Alkermes to Report First Quarter Financial Results on May 1, 2024
Alkermes to Report First Quarter Financial Results on May 1, 2024 PR Newswire
09.04.24 - PR Newswire
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic ...
09.04.24 - PR Newswire
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic ...
08.04.24 - PR Newswire
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society PR ...
08.04.24 - PR Newswire
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society PR ...
07.03.24 - PR Newswire
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors PR Newswire
07.03.24 - PR Newswire
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors PR Newswire
15.02.24 - PR Newswire
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 PR Newswire
15.02.24 - PR Newswire
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 PR Newswire
08.02.24 - PR Newswire
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 PR Newswire
08.02.24 - PR Newswire
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 PR Newswire
03.01.24 - PR Newswire
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
03.01.24 - PR Newswire
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire

Newssuche

Videos

newspaper
08:35 Uhr -14,29%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »